A detailed history of Cito Capital Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cito Capital Group, LLC holds 29,000 shares of BMY stock, worth $1.62 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
29,000
Previous 30,900 6.15%
Holding current value
$1.62 Million
Previous $1.68 Million 28.16%
% of portfolio
0.47%
Previous 0.69%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$40.25 - $52.99 $76,475 - $100,681
-1,900 Reduced 6.15%
29,000 $1.2 Million
Q1 2024

May 15, 2024

BUY
$47.98 - $54.4 $91,162 - $103,360
1,900 Added 6.55%
30,900 $1.68 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $19,392 - $23,140
400 Added 1.4%
29,000 $1.49 Million
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $34,734 - $38,838
600 Added 2.14%
28,600 $1.66 Million
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $31,855 - $35,370
500 Added 1.82%
28,000 $1.79 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $32,855 - $37,265
500 Added 1.85%
27,500 $1.91 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $390 - $230,520
-3,000 Reduced 10.0%
27,000 $1.92 Million
Q3 2021

Nov 10, 2021

SELL
$59.17 - $69.31 $177,510 - $207,930
-3,000 Reduced 9.09%
30,000 $1.79 Million
Q1 2021

May 17, 2021

BUY
$59.34 - $66.74 $59,340 - $66,740
1,000 Added 3.13%
33,000 $2.1 Million
Q3 2020

Nov 16, 2020

SELL
$57.43 - $63.64 $28,715 - $31,820
-500 Reduced 1.54%
32,000 $1.93 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $98,420 - $128,380
2,000 Added 6.56%
32,500 $2.09 Million
Q1 2019

May 13, 2019

BUY
$45.12 - $53.8 $45,120 - $53,800
1,000 Added 3.39%
30,500 $1.46 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $1.63 Million - $1.88 Million
29,500
29,500 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $119B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Cito Capital Group, LLC Portfolio

Follow Cito Capital Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cito Capital Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cito Capital Group, LLC with notifications on news.